Gilead Sciences 2022: The residue of designIssue Archives, October 2022, TherapeuticsIt might seem like luck for a company to trip over a multi-billion dollar COVID treatment already lurking in its pipeline – but perhaps not so much when that company, Gilead, has been at the leading edge of antiviral R&D for decades. Read more October 11, 2022/by Joshua Slatko https://www.pharmalive.com/wp-content/uploads/2019/10/Biktarvy.jpg 1286 1800 Joshua Slatko https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Joshua Slatko2022-10-11 03:50:592022-10-04 16:12:39Gilead Sciences 2022: The residue of design